	US 11,679,113 B2
	Anticancer treatment for uveal melanoma
Jorge Gutkind, La Jolla, CA (US); David Schlaepfer, La Jolla, CA (US); Justine Paradis, La Jolla, CA (US); Ayush Kishore, La Jolla, CA (US); Monica Acosta, La Jolla, CA (US); and Nadia Arang, La Jolla, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Mar. 19, 2020, as Appl. No. 16/824,639.
Claims priority of provisional application 62/832,425, filed on Apr. 11, 2019.
Prior Publication US 2020/0323863 A1, Oct. 15, 2020
Int. Cl. A61P 35/04 (2006.01); A61K 31/506 (2006.01); A61K 31/5355 (2006.01); A61K 31/437 (2006.01); A61K 31/136 (2006.01); A61K 31/4402 (2006.01); A61K 31/166 (2006.01); A61K 31/4184 (2006.01); A61K 31/519 (2006.01); A61K 31/44 (2006.01); A61K 31/4523 (2006.01); A61K 31/53 (2006.01); A61K 31/4439 (2006.01); A61K 48/00 (2006.01); A61K 31/5025 (2006.01)

CPC A61K 31/5355 (2013.01) [A61K 31/5025 (2013.01); A61K 48/005 (2013.01); A61P 35/04 (2018.01)]

9 Claims

1. A method for treating primary or metastatic uveal melanoma (UM) in a subject in need thereof comprising administering an effective amount of a first agent that inhibits expression of focal adhesion kinase (FAK) and a second agent that inhibits mitogen-activated protein kinase kinase (MEK), wherein the first agent is one or more of: PF-562271, VS-4718, NVP-TAC544, TAE226, VS-6063, 1H-Pyrrolo(2,3-b)pyridine, Y15 (1,2,4,5-benzenetetraamine tetrahydrochloride), chloropyramine hydrochloride, R2, Y11, PF-562,271, or GSK2256098 and wherein the second agent is one or more of: selumetinib, trametinib, cobimetinib, CH5126766, Binimetinib, AZD-8330, PD-325901, CI-1040, or TAK-733.